Scarica l'app Stockscreener
2.24
2.75%
0.06
Dopo l'orario di chiusura:
2.25
0.010
+0.45%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.18
Aprire:
$2.16
Volume 24 ore:
8.06M
Relative Volume:
0.59
Capitalizzazione di mercato:
$889.21M
Reddito:
$241.53M
Utile/perdita netta:
$-389.92M
Rapporto P/E:
-1.8211
EPS:
-1.23
Flusso di cassa netto:
$-323.54M
1 W Prestazione:
-9.31%
1M Prestazione:
-1.32%
6M Prestazione:
+27.64%
1 anno Prestazione:
-72.82%
Intervallo 1D:
$2.09
$2.25
Intervallo di 1 settimana:
$2.09
$2.62
Portata 52W:
$1.6385
$9.70
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Nome
Iovance Biotherapeutics Inc
Settore
Industria
Telefono
(650) 260-7120
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS
Confronta IOVA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.24 | 865.39M | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-16 | Downgrade | UBS | Buy → Neutral |
| 2025-05-12 | Downgrade | Truist | Buy → Hold |
| 2025-05-09 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-07-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-09-18 | Reiterato | Barclays | Overweight |
| 2023-05-30 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-31 | Iniziato | Guggenheim | Neutral |
| 2022-08-18 | Ripresa | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2021-06-10 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Downgrade | Stifel | Buy → Hold |
| 2021-05-03 | Iniziato | Truist | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2021-03-08 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Iniziato | Mizuho | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-02-26 | Reiterato | Oppenheimer | Outperform |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-04-29 | Iniziato | Piper Jaffray | Overweight |
| 2019-02-28 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-07 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-31 | Ripresa | B. Riley FBR | Buy |
| 2018-07-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-04-10 | Aggiornamento | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Reiterato | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-01 | Reiterato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Globe and Mail
Iovance (NASDAQ: IOVA) grants inducement stock options on 164,900 shares at $2.18 - Stock Titan
Is Iovance Biotherapeutics Inc. stock gaining market shareWall Street Watch & Risk Managed Investment Signals - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock remains stable2025 Performance Recap & Free Technical Confirmation Trade Alerts - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock gets analyst attentionJuly 2025 Market Mood & Precise Entry and Exit Recommendations - newser.com
What technical patterns form on Iovance Biotherapeutics Inc. (2LB) stock charts - newser.com
How Iovance Biotherapeutics Inc. (2LB) stock compares with market leadersMarket Movement Recap & AI Based Buy and Sell Signals - newser.com
Quantitative breakdown of Iovance Biotherapeutics Inc. recent moveGlobal Markets & High Accuracy Swing Entry Alerts - newser.com
Strategies to average down on Iovance Biotherapeutics Inc.Portfolio Growth Summary & Stepwise Trade Execution Plans - newser.com
Can Iovance Biotherapeutics Inc. stock deliver sustainable ROEJuly 2025 Breakouts & Expert Approved Momentum Trade Ideas - newser.com
Why Iovance Biotherapeutics Inc. stock appeals to analystsJuly 2025 Catalysts & Fast Gaining Stock Strategy Reports - newser.com
Is Iovance Biotherapeutics Inc. (2LB) stock overpriced at current multiplesJuly 2025 Momentum & Free Expert Approved Momentum Trade Ideas - newser.com
Does Iovance Biotherapeutics Inc. stock trade at a discount to peersJuly 2025 Short Interest & Weekly Chart Analysis and Guides - newser.com
Can Iovance Biotherapeutics Inc. (2LB) stock resist broad market declinesJuly 2025 Rallies & AI Powered Market Entry Strategies - newser.com
Iovance Biotherapeutics: Investigation and Financial Strategies - StocksToTrade
Why Iovance Biotherapeutics Inc. (2LB) stock is listed among top recommendationsQuarterly Growth Report & Accurate Trade Setup Notifications - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock attracts wealthy investors - newser.com
Why Iovance Biotherapeutics Inc. stock attracts global investorsJuly 2025 Drop Watch & Smart Allocation Stock Reports - newser.com
Published on: 2025-11-19 04:39:30 - newser.com
Published on: 2025-11-19 00:55:20 - newser.com
What earnings margins imply for Iovance Biotherapeutics Inc. (2LB) stock2025 Year in Review & Real-Time Volume Analysis Alerts - newser.com
Iovance Biotherapeutics Inc Azioni (IOVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):